Halneuron - (HALT-CINP / HAL-CINP-203)

October 6, 2026: Dogwood Therapeutics (NASDAQ: DWTX) said management will participate in the 2026 Maxim Growth Summit on October 12-14, 2026, in New York, with CEO Greg Duncan meeting investors and Maxim analysts.

The catalyst-relevant update is that Dogwood recently completed enrollment in its Phase 2b Halneuron trial and expects topline data in November 2026. Halneuron is being developed for pain conditions including chemotherapy-induced neuropathic pain (CINP) and has FDA Fast Track designation for CINP.

The company also said its pipeline includes SP16 IV, a program for neuropathy and prevention or repair of nerve damage following chemotherapy. A forthcoming Phase 1b CIPN trial for SP16 IV is fully funded by the National Cancer Institute.